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Analytic morphomics identiﬁes predictors of
new-onset diabetes after liver transplantation
Vaughn VM, Cron DC, Terjimanian MN, Gala ZS, Wang SC, Su
GL, Volk ML. Analytic morphomics identiﬁes predictors of new-
onset diabetes after liver transplantation.
Abstract: Among liver transplant recipients, development of post-
transplant complications such as new-onset diabetes after transplantation
(NODAT) is common and highly morbid. Current methods of predicting
patient risk are inaccurate in the pre-transplant period, making
implementation of targeted therapies diﬃcult. We sought to determine
whether analytic morphomics (using computed tomography scans) could
be used to predict the incidence of NODAT. We analyzed peri-transplant
scans from 216 patients with varying indications for liver transplantation,
among whom 61 (28%) developed NODAT. Combinations of visceral
fat, subcutaneous fat, and psoas area were considered in addition to
traditional risk factors. On multivariate analysis adjusting for usual risk
factors such as type of immunosuppression, subcutaneous fat thickness
remained signiﬁcantly associated with NODAT (OR = 1.43, 95% CI
1.00–1.88, p = 0.047). Subgroup analysis showed that patients with later-
onset of NODAT had higher visceral fat, whereas subcutaneous fat
thickness was more correlated with earlier-onset of NODAT (using
10 months post-transplant as the cut-oﬀ).
Conclusion: Analytic morphomics may be used to help assess NODAT
risk in patients undergoing liver transplantation.
Valerie M. Vaughna,*, David C.
Cronb,c,*, Michael N. Terjimanianb,c,
Zachary S. Galab,c, Stewart C.
Wangb,c, Grace L. Sub,d,e and
Michael L. Volke
aDepartment of Internal Medicine, University of
Michigan Medical School, bMorphomic
Analysis Group, University of Michigan
Medical School, cDepartment of Surgery,
University of Michigan Medical School, dVA
Ann Arbor Health Care System and eDivision of
Gastroenterology, University of Michigan
Medical School, Ann Arbor, MI, USA
Key words: analytic morphomics – body
composition – cirrhosis – liver disease –
metabolic syndrome – new-onset diabetes
after transplantation
Corresponding author: Valerie M. Vaughn, MD,
Department of Internal Medicine, University of
Michigan Medical School, 3110 Taubman Ctr,
SPC 5368, Ann Arbor, MI 48109-5362, USA.
Tel.: +1 734 936 4340;
fax: +1 734 936 3654;
e-mail: valmv@med.umich.edu
*These authors contributed equally to this
work.
Conflict of interest: None.
Accepted for publication 2 March 2015
Liver transplantation is the only cure for end-
stage liver disease and is an increasingly utilized
treatment for hepatocellular carcinoma (HCC)
in select populations. Despite improved survival
with transplantation, recipients are at risk for a
host of metabolic phenomena post-transplant
due to transplant medications, resumption of
previous dietary habits, and their underlying
disease processes. New-onset diabetes after
transplantation (NODAT) is particularly com-
mon, with a reported incidence of 10.8–61%
(1–4), and is linked to increased cardiovascular
events, mortality, and other complications (2, 5,
6).
Accurately predicting which patients will
develop NODAT could lead to interventions to
ameliorate these complications. Established risk
factors for NODAT include prolonged prednisone
use, tacrolimus immunosuppression, HCC, and
hepatitis C (HCV) (1, 7). It is known that body
composition – speciﬁcally body mass index (BMI),
waist circumference, and waist to hip ratio (i.e.,
“pear-shape”) – is correlated with the development
of diabetes in non-cirrhotic populations. However,
these measurements are diﬃcult to apply in pre-
transplant patients who have varying degrees of
ascites, subcutaneous edema, and sarcopenia that
make these measurements inaccurate.
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The emerging ﬁeld of analytic morphomics has
enabled us to make more precise measurements of
body composition using computed tomography
(CT) scans. It has been shown that morphomic
measures of fat distribution and quantiﬁcation of
trunk musculature using CT scans can help quan-
tify surgical risk in a variety of populations, includ-
ing liver transplant recipients (8–12). In addition, it
has been shown that visceral adiposity and relative
skeletal muscle mass in non-transplant patients are
associated with the development of insulin resis-
tance (13, 14). To our knowledge, there have been
no studies investigating the utility of these mea-
sures in predicting NODAT in liver transplant
recipients.
We therefore aimed to determine whether ana-
lytic morphomics could be used to predict the inci-
dence of NODAT in patients undergoing liver
transplantation. We hypothesized that higher fat
and lower trunk muscle size would be associated
with NODAT.
Methods
Study population
This study was approved by the University of
Michigan Institutional Review Board. This was
a retrospective study of adult patients who
underwent liver transplantation at a single large
academic hospital between 2000 and 2011 with
available peri-operative CT imaging. Eligible
scans were those within 90 d of the operation
that included the L4 vertebral level. We further
narrowed this group to include only those
patients without documented diabetes at the
time of transplantation. Lastly, we excluded
patients who died within the ﬁrst 10 months
post-transplant. This subset served as our study
cohort (Fig. 1). The following demographic and
clinical characteristics were collected retrospec-
tively from the electronic medical records: recipi-
ent age, gender, race, height, weight, BMI,
serum albumin, model for end-stage liver disease
score, liver disease etiology (or etiologies if mul-
tiple; see Table S1 for descriptions), tobacco use,
diabetes family history, hyperlipidemia diagnosis,
and immunosuppressive regimen active at
10 months post-transplant (tacrolimus, cyclo-
sporine, and prednisone). Chart review was per-
formed using the electronic medical record
search engine (EMERSE) to query clinical
documentation of these characteristics (15). At
conclusion of this step, 10% of charts were
manually reviewed by a single physician reviewer
for quality assurance.
Analytic morphomics
Fig. 2 shows the morphomic measures considered
in this analysis: total psoas area, visceral fat area,
subcutaneous fat area, and anterior subcutaneous
fat thickness. We also considered the following
ratios: visceral fat to subcutaneous fat areas, vis-
ceral fat to total psoas areas, and subcutaneous fat
to total psoas areas. CT scans were processed using
semi-automated methods programmed into MAT-
Fig. 1. Selection criteria. Patients were included if they had
undergone transplant between 2000 and 2011 and had avail-
able peri-operative computed tomography (CT) imaging and
did not carry a diagnosis of diabetes at the time of transplant.
Patients who died within the ﬁrst 10 months after transplant
were excluded.
Fig. 2. Morphomic measurements. Morphomic measurements
calculated from computed tomography scans are shown above.
The fascia is outlined, and within this region, the visceral fat is
portrayed by a heat map of density. The skin and the psoas
muscles are outlined as well.
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LAB v. 2013a (MathWorks, Natick, MA, USA)
after de-identiﬁed DICOM ﬁles were loaded in the
morphomics server. The methods for measuring
total psoas area are well described elsewhere (8, 9).
Initially, each scan was anatomically indexed in a
semi-automated fashion so that precise measure-
ments could be made referenced to vertebral level
(16). The cross-sectional areas of the left and right
psoas muscles were computed inferior to the L4
vertebral level. These areas were summed to com-
pute total psoas area, and this measurement was
adjusted for the average Hounsﬁeld units (density)
of the psoas muscle to account for fatty inﬁltration
(9). The resulting measure is termed lean psoas
area.
Fat areas were measured at L4 as well for consis-
tency. The fascial and skin envelopes were identi-
ﬁed automatically after user-deﬁned identiﬁcation
of several pelvic points and the linea alba. This was
followed by user veriﬁcation and editing as needed.
Within the fascial envelope, the Hounsﬁeld units of
each pixel were calculated, and any pixels that fell
within the density range of fat were deemed vis-
ceral fat. Between the skin and fascia contours,
Hounsﬁeld units were again used to identify subcu-
taneous fat. Because many larger patients have lat-
eral regions of their subcutaneous fat cropped out
of the CT images, we also included anterior subcu-
taneous fat thickness as a measure, which was
available on all patients. This measure was com-
puted as the shortest distance between the fascia
and skin contours at the linea alba. Because a lin-
ear distance measure is more subject to random
variation than area measurements, this measure
was averaged across the T12 to L4 vertebral levels
(17).
Outcome
The primary outcome of interest was combined
NODAT – deﬁned as incidence of NODAT at or
beyond 10 months post-transplant. Because our
follow-up began at 10 months post-transplant,
we censored out patients who died prior to this
10-month mark. Ten months has been used as
the threshold in prior studies, as by this time,
most patients are clinically stable, have been
taken oﬀ steroids, and are therefore more likely
to have stable blood sugars. This allows us to
avoid misclassifying transient diabetes as NO-
DAT (1). Other studies have used six or
12 months as thresholds; however, diﬀerences in
incidence between the two periods were similar,
and therefore, the exact time point is likely not
signiﬁcant (4, 6). For descriptive purposes, we
also subdivided NODAT into “earlier-onset”
(NODAT incident prior to and persistent
through the 10-month time point) and “later-
onset” (NODAT incident beyond 10 months).
We used EMERSE to retrospectively review the
electronic medical records for mention of the fol-
lowing terms: NODAT, diabetes, DM, hyperglyce-
mia, and insulin. For patients identiﬁed in this
manner, we veriﬁed true diagnosis of NODAT
according to the following American Diabetes
Association criteria: A1C ≥ 6.5, fasting plasma
glucose ≥ 126, oral glucose tolerance test at
two h ≥ 200, random glucose ≥ 200, or any insu-
lin use.
Statistical analysis
Descriptive statistics were computed for the study
cohort. Categorical variables were summarized by
frequency tables and compared using a chi-square
test or Fisher’s exact test, as appropriate. Continu-
ous variables were summarized by mean and stan-
dard deviation and compared using a Student’s
t-test or a Wilcoxon rank-sum test, as appropriate.
For regression analysis, morphomic variables were
standardized by gender to facilitate interpretation
of the regression coeﬃcients, and the outcome was
combined NODAT incidence (therefore including
earlier-onset and later-onset). Logistic regression
was used to identify factors associated with NO-
DAT incidence on bivariate analysis. Variables
with a p-value ≤ 0.20 were considered “candidate
predictors.” Multivariate logistic regression was
then applied to identify factors independently asso-
ciated with NODAT incidence. All candidate pre-
dictors and clinically relevant variables were
entered into the logistic regression analysis, and
backward stepwise selection was used to determine
a subset of adjustment covariates. Predictive ability
of the models was assessed using the area under
the receiver operating characteristic (C-statistic).
Model goodness of ﬁt was veriﬁed using the Hos-
mer–Lemeshow test. All statistical analysis was
performed using STATA v. 13 (College Station,
TX, USA).
Results
Two hundred and sixteen patients met our inclu-
sion criteria. Table 1 displays the demographic
and clinical characteristics of this cohort. The most
common underlying reasons for liver transplanta-
tion were HCV (37.5%), alcoholic cirrhosis
(26.9%), HCC (26.4%), and cholestatic disease
(19.9%). The majority of patients (79.6%) were on
tacrolimus, and 42.1% of patients were on predni-
sone at 10 months post-transplant. The overall
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incidence of NODAT was 28.2% (61 patients). Of
these patients, 77.1% (47 patients) had earlier-
onset NODAT (present at 10 months post-trans-
plant) and 23.0% (14 patients) had later-onset
NODAT (incident beyond 10 months post-trans-
plant). Of this latter group, the median time from
transplant to diagnosis of NODAT was
26 months.
Table 2 displays the estimated (unadjusted)
parameters for morphomic variables from the
logistic regression analyses of the primary outcome
(combined NODAT). In bivariate analysis, ante-
rior subcutaneous fat thickness was the only signif-
icant morphomic predictor of NODAT (odds ratio
[OR] = 1.43 per standard deviation increase, 95%
CI 1.07–1.92, p = 0.02). Other variables signiﬁ-
cantly associated with NODAT incidence in bivari-
ate analysis included tobacco use in the past
year (p = 0.03), HCV (p = 0.005), and cholestatic
disease (which was protective; p = 0.004). The
overall distribution for anterior subcutaneous fat
thickness was skewed right, and values ranged
from 2.3 to 50.9 mm. There was a strong positive
correlation between anterior subcutaneous fat
thickness and subcutaneous fat area (r = 0.80).
In multivariate analysis, subcutaneous fat thick-
ness remained signiﬁcantly associated with
NODAT (OR = 1.43, 95% CI 1.00–1.88, p = 0.047),
along with HCV, and “other” diagnosis (see
Table S1 for description of “other” diagnosis).
BMI was not signiﬁcantly diﬀerent. Cholestatic
disease was removed from multivariate analysis
because it was mutually exclusive with HCV and
therefore predicted each other in modeling. The C-
statistic for this model was 0.70. The covariates in
this model were then used to calculate adjusted
rates of NODAT incidence. Fig. 3 shows these
Table 1. Patient characteristics by NODAT status
Overall No NODAT Combined NODAT p-Value
Total n 216 155 61
Age 49.5  10.1 49.5  10.3 49.0  9.9 0.63
Male gender 60.6% (131) 59.4% (92) 63.9% (39) 0.54
Non-white race 17.1% (37) 15.5% (24) 21.3% (13) 0.31
BMI 27.0  5.7 26.7  5.8 27.7  5.6 0.24
MELD 18.6  7.6 18.7  7.6 18.2  7.5 0.68
Albumin 2.8  0.6 2.8  0.6 2.8  0.6 0.46
Tobacco use (past year)* 24.1% (52) 20.0% (31) 34.4% (21) 0.03
Hyperlipidemia 13.0% (28) 15.5% (24) 6.6% (4) 0.09
Cardiovascular disease 2.3% (5) 3.2% (5) 0 0.33
Diabetes family history 39.8% (86) 37.4% (58) 45.9% (28) 0.25
Tacrolimus 79.6% (172) 78.1% (121) 83.6% (51) 0.36
Cyclosporine 20.4% (44) 21.9 (34) 16.4 (10) 0.36
Prednisone 42.1% (91) 40.6% (63) 45.9% (28) 0.48
Liver pathology
Alcoholic 26.9% (58) 27.1% (42) 26.2% (16) 0.90
Autoimmune hepatitis 4.6% (10) 3.9% (6) 6.6% (4) 0.47
Hepatocellular carcinoma 26.4% (57) 26.5% (41) 32.8% (20) 0.35
Cholestatic* 19.9% (43) 25.2% (39) 6.6% (4) 0.004
Fulminant 3.7% (8) 3.9% (6) 3.3% (2) 0.84
Hepatitis B virus 6.0% (13) 6.5% (10) 4.9% (3) 0.67
Hepatitis C virus* 37.5% (81) 31.6% (49) 52.5% (32) 0.005
NAFLD 6.5% (14) 7.1% (11) 4.9% (3) 0.56
Other 8.8% (19) 7.1% (11) 13.1% (8) 0.17
Combined NODAT includes both earlier-and later-onset NODAT.
NODAT, new-onset diabetes after transplantation.
*Represents a significant difference when comparing no NODAT to combined NODAT (p ≤ 0.05).
Table 2. Estimated morphomic coefficients from bivariate logistic
regression for combined NODAT
OR p-Value
Morphomic features
Subcutaneous fat area (SD units) 1.18 0.262
Visceral fat area (SD units) 1.07 0.663
Visceral fat to subcutaneous fat (ratio) 1.07 0.652
Anterior subcutaneous fat thickness (SD units)* 1.43 0.017
Lean psoas area (SD units) 1.10 0.513
Subcutaneous fat to lean psoas (ratio) 1.01 0.469
Visceral fat to lean psoas (ratio) 1.02 0.622
Combined NODAT includes both earlier- and later-onset NODAT.
NODAT, new-onset diabetes after transplantation.
*Represents a significant difference when comparing no NODAT to com-
bine NODAT (p = 0.05).
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rates by gender-stratiﬁed tertile of anterior subcu-
taneous fat thickness. Patients with the most ante-
rior subcutaneous fat had 1.7-fold higher incidence
of NODAT compared to patients with the least
anterior subcutaneous fat.
For our secondary analysis, we divided patients
into earlier-onset and later-onset NODAT. Table 3
shows the median morphomic values for the fol-
lowing three groups of patients: those without NO-
DAT, those with earlier-onset NODAT, and those
with later-onset NODAT. Compared to patients
without NODAT, visceral fat area and the ratio of
visceral fat to lean psoas area were signiﬁcantly lar-
ger in the later-onset NODAT group (visceral fat
area: p = 0.02; ratio: p = 0.01). Compared to
patients without NODAT, anterior subcutaneous
fat thickness was signiﬁcantly larger in both the
earlier-onset group (p = 0.04) and the later-onset
group (p = 0.02).
As a sensitivity analysis, we compared the mor-
phomic characteristics of patients with diabetes at
the time of transplant (excluded initially from our
main cohort) and patients in our cohort who devel-
oped NODAT (Table S2). Compared to diabetic
liver transplant candidates, the onset NODAT
patients had signiﬁcantly lower visceral fat
(p = 0.002), larger lean psoas area (p = 0.02), and
smaller ratios of subcutaneous fat to leas psoas
area (p = 0.001) and smaller visceral fat to lean
psoas area (p < 0.001). The later-onset NODAT
patients were similar to the diabetic comparison
group in all morphomic aspects. The patients in
our study cohort who did not develop NODAT
were signiﬁcantly diﬀerent from the diabetic com-
parison group in all morphomic aspects (lower fat
and larger muscles in the patients without NO-
DAT) except the ratio of visceral to subcutaneous
fat.
Tacrolimus use was not found to be signiﬁcant
in bivariate or multivariate modeling. As a sensitiv-
ity analysis, we ran the models again using average
tacrolimus trough levels from date of transplant to
six months post-transplant (data available for all
but six patients). By itself, average tacrolimus
trough was a signiﬁcant predictor of NODAT, but
this measure was not signiﬁcant when adjusting for
subcutaneous fat thickness or when included in the
multivariate model.
Discussion
This is the ﬁrst study evaluating analytic morpho-
mics in a liver transplant population to determine
associations with NODAT. We found that subcu-
taneous fat thickness was independently associated
with NODAT, even after adjustment for other clin-
ical and demographic characteristics. In addition,
visceral fat area and the ratio of visceral fat to lean
psoas were associated with later-onset (beyond
10 months) NODAT. The incidence of NODAT in
our study was 28.2% – well within typical values
found in other studies (1–4). Similar to other stud-
ies, the variables we found to be associated with
Fig. 3. Adjusted incidence of combined new-onset diabetes
after transplantation (NODAT) by tertile of subcutaneous fat
thickness. After adjustment for hepatitis C, hyperlipidemia,
and “other” diagnoses, patients with the most anterior subcu-
taneous fat had a 1.7-fold higher incidence of NODAT com-
pared to the patients with the least anterior subcutaneous fat
(36% compared with 21%). Combined NODAT includes both
earlier- and later-onset NODAT.
Table 3. Median morphomic values by timing of NODAT incidence
No NODAT (n = 152) Earlier-onset NODAT (n = 47) Later-onset NODAT (n = 14)
Visceral fat area (mm2) 6234 6975 10 147*
Subcutaneous fat area (mm2) 15 474 15 493 16 240
Visceral fat to subcutaneous fat (ratio) 0.5 0.4 0.6
Anterior subcutaneous fat thickness (mm) 15 18* 23*
Lean psoas area (mm2) 1545 1843 1525
Subcutaneous fat to lean psoas (ratio) 9.3 10.2 11.5
Visceral fat to lean psoas (ratio) 3.8 3.7 6.9*
NODAT, new-onset diabetes after transplantation; Earlier-onset, NODAT incident prior to and persistent through 10 months post-transplant; Later-onset,
NODAT incident beyond 10 months.
*Represents a significant difference when compared to those without NODAT (p ≤ 0.05).
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NODAT included tobacco use and HCV, with
cholestatic disease being protective from NODAT.
However, not all previously proven risk factors
(e.g., HCC and tacrolimus use) were found to be
statistically signiﬁcant, likely due to the small sam-
ple size and to the relatively large percentage of
patients on tacrolimus rather than cyclosporine or
other agents.
As with all retrospective studies, we were lim-
ited by the data collection available in the chart,
and it is possible that not all patients had ade-
quate testing for NODAT or that risk factors were
not mentioned within the chart. We attempted to
mitigate this factor by searching broadly for mul-
tiple search terms and including both chart review
and laboratory data in determining NODAT sta-
tus. In addition, this study is susceptible to selec-
tion bias, as only those patients who had CT
scans and who maintained follow-up could be
included. We were not able to measure all factors
associated with NODAT as caloric intake and
exercise are diﬃcult to measure retrospectively.
Although we attempted to correct for any mea-
sured confounders using logistic regression, retro-
spective studies are prone to these types of biases
and do not prove causality. A larger prospective
study would need to be undertaken to verify our
ﬁndings. Concerning our deﬁnition of NODAT,
there is no clear consensus on a temporal deﬁni-
tion; we chose presence at 10 months post-trans-
plant as our threshold. We also ran the analyses
using survival analysis techniques (time until NO-
DAT onset) and we observed the same ﬁndings,
with subcutaneous fat thickness as the only signiﬁ-
cant morphomic predictor (data not shown).
Finally, this is a single-center study, and therefore,
results from our population may not be generaliz-
able to other centers.
Other studies have shown visceral fat at the L4
umbilicus and visceral to subcutaneous fat ratio
to be related to surgical risk and diabetes; how-
ever, we did not ﬁnd these measurements to be
signiﬁcant in our cohort (12, 13). In our sample,
we found that subcutaneous fat could not be ade-
quately measured in 12% of patients due to crop-
ping of CT scan images on the lateral aspects of
the ﬁeld, presumably underestimating subcutane-
ous fat for these patients. By using midline sub-
cutaneous fat, which is correlated with total
subcutaneous fat, this limitation was eliminated
leaving us with an easy-to-measure variable that
is correlated with NODAT. Midline subcutaneous
fat could also reﬂect a diﬀerent body shape or fat
distribution that predisposes to diabetes. Alterna-
tively, fat thickness may be less confounded by
body size, making it a more reliable measure of
fat. We did observe signiﬁcantly higher visceral
fat in the later-onset NODAT patients and more
similarities between the morphomics of later-
onset patients and patients who had diabetes pre-
transplant. This could possibly point to a bio-
chemical diﬀerence between earlier- and later-
onset diabetes. Patients who develop later-onset
NODAT may be genetically or physically pre-dis-
posed to diabetes (i.e., they would have devel-
oped diabetes eventually without a transplant).
Those with earlier-onset NODAT may instead
have developed diabetes due to immunosuppres-
sion or other transplant-related factors. Due to
small sample size, we were unable to consider
timing of NODAT incidence in our primary mul-
tivariate analysis. This ﬁnding merits further
study as this would help to reveal a population at
risk for NODAT that might not be normally con-
sidered at risk.
Given the high morbidity associated with NO-
DAT, it is imperative that high-risk patients are
identiﬁed early so that modiﬁable risk factors can
be addressed and corrected. The 2003 International
Consensus Guidelines recommend evaluating and
identifying patients at risk for NODAT during the
initial consult for transplantation (18). Pre-trans-
plant patients often undergo pre-operative cross-
sectional imaging in the course of their work-up
and for HCC screening. By using these already
available imaging scans, we can further identify at-
risk patients who would merit individualized
weight, diet, and exercise counseling, which has
been shown to prevent diabetes in high-risk
patients (19). Additional interventions could target
immunosuppressive therapy by focusing on mini-
mizing steroids (18). In conclusion, our study
shows that analytic morphomics may be useful for
assessing NODAT risk in patients undergoing liver
transplantation.
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